WO1991011206A1 - Alginate materials - Google Patents
Alginate materials Download PDFInfo
- Publication number
- WO1991011206A1 WO1991011206A1 PCT/GB1991/000119 GB9100119W WO9111206A1 WO 1991011206 A1 WO1991011206 A1 WO 1991011206A1 GB 9100119 W GB9100119 W GB 9100119W WO 9111206 A1 WO9111206 A1 WO 9111206A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alginate
- cation
- alginate material
- cations
- membrane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- the present invention relates alginate materials which are useful particularly (but not exclusively) for wound dressings.
- alginate materials have haemostatic and wound healing properties and may be used in various types of wound dressing * (see for example EP-A- 0 236 104 (Courtauld ⁇ ) ) .
- alginates for wound dressings are prepared by spinning a solution of sodium alginate into a ' bath containing calcium ions (usually provided by calcium chloride) so that alginate material precipitates in the form of the insoluble calcium salt.
- calcium ions usually provided by calcium chloride
- the alginates are highly hydrophilic and have thus found particular use in the dressing of "highly exuding" wounds where this absorbing allows comparatively large quantities of exudate to be absorbed before the alginate material dissolves.
- an alginate material which comprises of zinc, copper, silver, cerium, manganese, or cobalt cations and/or any cation which is an enzyme co-factor, save that the cation is not solely calcium, sodium or a mixture of these two cations.
- Enzyme co-factors include Mg 2+ , Co 2+ , Mn + and Fe 3+ ions.
- the cation (or mixture of abovementioned cations) provide exchangeable ions which have useful wound healing properties and the alginate serves as a base material for the delivery of these cations to the wound site.
- the absorbency of the alginate material is an added advantage.
- the minimum amount of the cation incorporated in the alginate material is preferably (l/2n) moles (of cation) per mole of sugar residue in the alginate.
- the minimum amount is preferably 0.25 moles.
- the preferred minimum amount is 0.5 moles (of cation).
- the preferred maximum amount for the cation is (1/n) moles per mole of sugar residue in the alginate.
- alginate materials of the invention may be used in a wide range of wound healing applications.
- One particular application is for the treatment of leg ulcers which might contain in excess of 10 5 organisms/ml.
- an alginate material containing copper ions may initially be applied to the ulcer and would cause the wound to flush itself.
- a further alginate material containing zinc ions may be applied to the ulcer to promote wound healing.
- the alginate material may be in the form of a porous membrane but is more preferably in the form of a porous fibrous material or of a particulate material of sufficiently small size for formulation into an aerosol (which may then be sprayed onto a wound) .
- a porous fibrous material produced, for example, as described below is particulary advantageous because of the high internal surface are avoidable for ion-exchange.
- Such a fibrous material may be produced by spinning a solution of a soluble alginate (particularly sodium or magnesium alginate) into bath containing the cations to be incorporated in the final alginate material.
- the solution may, for example, be spun into a bath by dissolving the chloride or nitrate of zinc and/or silver in water.
- Such fibrous materials may be supported in ' any suitable way for application to a wound site.
- the support may, for example, comprise a porous textile dressing or a porous membrane or a porous polymeric membrane comprised of a hydrophobic polymer defining a porous (particularly microporous) structure and a hydrophilic polymer provided at the surfaces, including the internal pore surfaces, of the hydrophobic polymer.
- a membrane is disclosed in WO-A-90/11820 (Beam Tech) .
- Particulate alginate material for formulation into an aerosol
- Particulate alginate material may be produced by subjecting particulate calcium alginate material to an ion exchange process with the appropriate cation(s).
- An alginate membrane may be produced by preparing an aqueous solution of a soluble alginate material, forming the solution into the shape of a membrane, and treating the thus formed membrane precursor with a liquid containing cations which precipitate alginate material from solution as a porous membrane.
- the precipitation bath may be aqueous or may be or include a water miscible organic solvent (e.g. DMSO, DMF).
- a water miscible organic solvent e.g. DMSO, DMF.
Abstract
An alginate material useful particularly as a wound dressing incorporates cations selected from zinc, copper, silver, cerium, manganese, cobalt, or any cation which is an enzyme cofactor, save that the cation is not solely calcium, sodium or a mixture of these two cations.
Description
ALGINATE MATERIALS
The present invention relates alginate materials which are useful particularly (but not exclusively) for wound dressings.
It is known that alginate materials have haemostatic and wound healing properties and may be used in various types of wound dressing* (see for example EP-A- 0 236 104 (Courtauldε) ) .
Conventionally, alginates for wound dressings are prepared by spinning a solution of sodium alginate into a' bath containing calcium ions (usually provided by calcium chloride) so that alginate material precipitates in the form of the insoluble calcium salt. For certain applications, it may be desirable for the alginate to have a greater degree of solubility in body fluids, in which case the calcium alginate may be treated in a bath of sodium ions so that some of the calcium is replaced by sodium to provide a more soluble form.
The alginates are highly hydrophilic and have thus found particular use in the dressing of "highly exuding" wounds where this absorbing allows comparatively large quantities of exudate to be absorbed before the alginate material dissolves.
It is a object of the present invention to provide alginate materials with improved properties for the treatment of wounds.
According to the present invention there is provide an alginate material which comprises of zinc, copper, silver, cerium, manganese, or cobalt cations and/or any cation which is an enzyme co-factor, save that the cation is not solely calcium, sodium or a mixture of these two cations. Enzyme co-factors include Mg2+, Co2+, Mn + and Fe3+ ions.
In the alginate material of the invention, the cation (or mixture of abovementioned cations) provide exchangeable
ions which have useful wound healing properties and the alginate serves as a base material for the delivery of these cations to the wound site. The absorbency of the alginate material is an added advantage.
Assuming that the cation has an oxidation slate of n+ the minimum amount of the cation incorporated in the alginate material is preferably (l/2n) moles (of cation) per mole of sugar residue in the alginate. Thus, for a divalent ion (n=2) the minimum amount is preferably 0.25 moles. Similarly for a monovalent ion (n=l) the preferred minimum amount is 0.5 moles (of cation). The preferred maximum amount for the cation is (1/n) moles per mole of sugar residue in the alginate. Thus the preferred maximum for divalent cation (n=2) is 0.5 moles.
The ions shown below have the indicated properties:
Ion Wound Healing Property
Zn2+ promotes healing
Ag+ bactericidal action
Cu2+ anti-microbial, wound flushing
Ce + anti-immunosuppressant
Mn2+ enzyme (oxidase) co-factor
Co + enzyme co-factor
It will thus be appreciated that alginate materials of the invention may be used in a wide range of wound healing applications. One particular application is for the treatment of leg ulcers which might contain in excess of 105 organisms/ml. In this case, an alginate material containing copper ions may initially be applied to the ulcer and would cause the wound to flush itself. Subsequently, a further alginate material containing zinc ions may be applied to the ulcer to promote wound healing.
In order to assist delivery of the cations into the wound, it is possible to use an iontophoretic technique so as to "drive" the ions into the wound.
The alginate material may be in the form of a porous
membrane but is more preferably in the form of a porous fibrous material or of a particulate material of sufficiently small size for formulation into an aerosol (which may then be sprayed onto a wound) . The use of a porous fibrous material (produced, for example, as described below) is particulary advantageous because of the high internal surface are avoidable for ion-exchange.
Such a fibrous material may be produced by spinning a solution of a soluble alginate (particularly sodium or magnesium alginate) into bath containing the cations to be incorporated in the final alginate material. The solution may, for example, be spun into a bath by dissolving the chloride or nitrate of zinc and/or silver in water.
Such fibrous materials may be supported in 'any suitable way for application to a wound site. The support may, for example, comprise a porous textile dressing or a porous membrane or a porous polymeric membrane comprised of a hydrophobic polymer defining a porous (particularly microporous) structure and a hydrophilic polymer provided at the surfaces, including the internal pore surfaces, of the hydrophobic polymer. Such a membrane is disclosed in WO-A-90/11820 (Beam Tech) .
Particulate alginate material (for formulation into an aerosol) may be produced by subjecting particulate calcium alginate material to an ion exchange process with the appropriate cation(s).
An alginate membrane may be produced by preparing an aqueous solution of a soluble alginate material, forming the solution into the shape of a membrane, and treating the thus formed membrane precursor with a liquid containing cations which precipitate alginate material from solution as a porous membrane.
The precipitation bath may be aqueous or may be or include a water miscible organic solvent (e.g. DMSO, DMF).
Claims
1. An alginate material which incorporates cations selected from zinc, copper, silver, cerium, manganese, cobalt, or any cation which is an enzyme cofactor, save that the cation is not solely calcium, sodium or a mixture of these two cations.
2. A material as claimed in claim 1 including an enzyme cofactor selected from Mg2+, Co2+, Mn2+, and Fe3+.
3. An alginate material as claimed in claim 1 or 2 wherein the alginate material is in the form of a fibre, a membrane, a film, or in the form of particles.
4. An alginate material as claimed in claim 3 wherein the alginate material comprises particles in the form of an aerosol.
5. A wound dressing comprising an alginate material as claimed in any one of claims 1 to 3.
6. A wound dressing as claimed in claim 4 wherein the alginate material is associated with a porous membrane comprised of a hydrophobic polymer defining the porous structure and a hydrophilic polymer provided at the surfaces, including the internal pore surfaces, of the hydrophobic polymer.
7. A method of producing an alginate material as claimed in claim 1 comprising providing a solution of a soluble alginate (preferably sodium or magnesium alginate) in a precipitation bath which contains at least one of said cations.
8. A method as claimed in claim 6 wherein said soluble alginate is spun into the bath to produce a fibre.
9. A method as claimed in claim 6 wherein said solution of the soluble alginate material is formed into the shape of a membrane and introduced into the precipitation bath.
10. A material as claimed in any one of claims 1 to 4 wherein the cation has an oxidation state of n+ and the amount of the cation present in the alginate material is at least (l/2n) moles per mole of sugar residue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9001878.9 | 1990-01-26 | ||
GB909001878A GB9001878D0 (en) | 1990-01-26 | 1990-01-26 | Alginate materials |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991011206A1 true WO1991011206A1 (en) | 1991-08-08 |
Family
ID=10669992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1991/000119 WO1991011206A1 (en) | 1990-01-26 | 1991-01-28 | Alginate materials |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7227991A (en) |
GB (1) | GB9001878D0 (en) |
WO (1) | WO1991011206A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4204012A1 (en) * | 1992-02-12 | 1993-08-19 | Ulrich Prof Dr Zimmermann | MITOGEN-FREE SUBSTANCE, THEIR PRODUCTION AND USE |
WO1994000164A1 (en) * | 1992-06-29 | 1994-01-06 | C. V. Laboratories Limited | Sustained release alginate fibre and process for the preparation thereof |
WO1995004078A1 (en) * | 1993-07-30 | 1995-02-09 | University College London | Cell adhesion protein complexes with copper |
EP1153620A2 (en) * | 2000-05-12 | 2001-11-14 | Johnson & Johnson Medical Ltd. | Solid compositions exhibiting selective binding to dissolved iron |
US6372248B1 (en) * | 1994-10-28 | 2002-04-16 | Innovative Technologies Limited | Dehydrated hydrogels |
EP1252901A1 (en) * | 2001-04-25 | 2002-10-30 | Les Laboratoires Brothier | Powdered wound dressing and method for producing the same |
GB2392913A (en) * | 2002-09-11 | 2004-03-17 | Johnson & Johnson Medical Ltd | Complex of an anionic polysaccharide with silver |
WO2004024197A1 (en) | 2002-09-11 | 2004-03-25 | Johnson & Johnson Medical Limited | Wound dressing materials comprising complexes of anionic polysaccharides with silver |
WO2004084961A1 (en) * | 2003-03-28 | 2004-10-07 | Coloplast A/S | A wound dressing |
US6861570B1 (en) | 1997-09-22 | 2005-03-01 | A. Bart Flick | Multilayer conductive appliance having wound healing and analgesic properties |
EP1882482A2 (en) | 2001-09-12 | 2008-01-30 | ConvaTec Limited | Antibacterial wound dressing |
US7385101B2 (en) | 2001-12-20 | 2008-06-10 | Noble Fiber Technologies, Llc | Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same |
WO2009097672A2 (en) * | 2008-02-08 | 2009-08-13 | Luiz Eduardo Da Cruz | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix |
US8124826B2 (en) | 2003-11-18 | 2012-02-28 | Systagenix Wound Management (Us), Inc. | Antioxidant and antimicrobial wound dressing materials |
US8507652B2 (en) | 2008-02-08 | 2013-08-13 | Luis Eduardo da Cruz | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix |
US8728513B2 (en) | 2000-09-21 | 2014-05-20 | Convatec Technologies Inc. | Silver containing wound dressing |
EP1942851B1 (en) | 2005-11-02 | 2016-11-23 | BSN medical GmbH | Absorptive element to be mounted on human or animal skin surfaces |
WO2018214007A1 (en) | 2017-05-23 | 2018-11-29 | 惠州华阳医疗器械有限公司 | Antibacterial wound dressing and preparation method and application thereof |
US11061033B2 (en) | 2016-04-05 | 2021-07-13 | University of Pittsburgh—of the Commonwealth System of Higher Education | Assay for detection of bladder or prostate cancer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB629419A (en) * | 1946-12-05 | 1949-09-20 | Johnson & Johnson Great Britai | Improvements in and relating to surgical dressings |
GB976301A (en) * | 1960-10-27 | 1964-11-25 | Calmic Ltd | Preparation and use of alginates |
GB1255155A (en) * | 1968-10-30 | 1971-12-01 | Wallace Cameron & Company Ltd | Improvements in or relating to preformed surgical or medical dressings |
GB1328088A (en) * | 1969-09-27 | 1973-08-30 | Wallace Cameron Co Ltd | Solubilized alginic materials |
EP0243069A2 (en) * | 1986-04-17 | 1987-10-28 | JOHNSON & JOHNSON MEDICAL, INC. | Adhesive wound dressing |
-
1990
- 1990-01-26 GB GB909001878A patent/GB9001878D0/en active Pending
-
1991
- 1991-01-28 WO PCT/GB1991/000119 patent/WO1991011206A1/en unknown
- 1991-01-28 AU AU72279/91A patent/AU7227991A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB629419A (en) * | 1946-12-05 | 1949-09-20 | Johnson & Johnson Great Britai | Improvements in and relating to surgical dressings |
GB976301A (en) * | 1960-10-27 | 1964-11-25 | Calmic Ltd | Preparation and use of alginates |
GB1255155A (en) * | 1968-10-30 | 1971-12-01 | Wallace Cameron & Company Ltd | Improvements in or relating to preformed surgical or medical dressings |
GB1328088A (en) * | 1969-09-27 | 1973-08-30 | Wallace Cameron Co Ltd | Solubilized alginic materials |
EP0243069A2 (en) * | 1986-04-17 | 1987-10-28 | JOHNSON & JOHNSON MEDICAL, INC. | Adhesive wound dressing |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4204012A1 (en) * | 1992-02-12 | 1993-08-19 | Ulrich Prof Dr Zimmermann | MITOGEN-FREE SUBSTANCE, THEIR PRODUCTION AND USE |
WO1994000164A1 (en) * | 1992-06-29 | 1994-01-06 | C. V. Laboratories Limited | Sustained release alginate fibre and process for the preparation thereof |
US5690955A (en) * | 1992-06-29 | 1997-11-25 | E. R. Squibb & Sons, Inc. | Sustained release alginate fibre and process for the preparation thereof |
WO1995004078A1 (en) * | 1993-07-30 | 1995-02-09 | University College London | Cell adhesion protein complexes with copper |
US5798116A (en) * | 1993-07-30 | 1998-08-25 | University College London | Stabilized materials comprised of copper ion-containing fibronectin mats |
US6372248B1 (en) * | 1994-10-28 | 2002-04-16 | Innovative Technologies Limited | Dehydrated hydrogels |
US6861570B1 (en) | 1997-09-22 | 2005-03-01 | A. Bart Flick | Multilayer conductive appliance having wound healing and analgesic properties |
EP1153620A3 (en) * | 2000-05-12 | 2003-05-28 | Johnson & Johnson Medical Ltd. | Solid compositions exhibiting selective binding to dissolved iron |
EP1153620A2 (en) * | 2000-05-12 | 2001-11-14 | Johnson & Johnson Medical Ltd. | Solid compositions exhibiting selective binding to dissolved iron |
US10391197B2 (en) | 2000-09-21 | 2019-08-27 | Convatec Technologies Inc. | Silver containing wound dressing |
US8728513B2 (en) | 2000-09-21 | 2014-05-20 | Convatec Technologies Inc. | Silver containing wound dressing |
US10010647B2 (en) | 2000-09-21 | 2018-07-03 | Convatec Technologies Inc. | Silver containing wound dressing |
US9066989B2 (en) | 2000-09-21 | 2015-06-30 | Convatec Technologies Inc. | Silver containing wound dressing |
US9345805B2 (en) | 2000-09-21 | 2016-05-24 | Convatec Technologies Inc. | Silver containing wound dressing |
EP1252901A1 (en) * | 2001-04-25 | 2002-10-30 | Les Laboratoires Brothier | Powdered wound dressing and method for producing the same |
EP1882482A2 (en) | 2001-09-12 | 2008-01-30 | ConvaTec Limited | Antibacterial wound dressing |
US10342890B2 (en) | 2001-09-12 | 2019-07-09 | Convatec Limited | Antibacterial wound dressing |
US8828424B2 (en) | 2001-09-12 | 2014-09-09 | Convatec Limited | Antibacterial wound dressing |
US7385101B2 (en) | 2001-12-20 | 2008-06-10 | Noble Fiber Technologies, Llc | Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same |
GB2392913B (en) * | 2002-09-11 | 2007-04-04 | Johnson & Johnson Medical Ltd | Wound dressings comprising complexes of oxidised celluloses with silver |
US8461410B2 (en) | 2002-09-11 | 2013-06-11 | Ethicon, Inc. | Wound dressing materials comprising complexes of anionic polysaccharides with silver |
WO2004024197A1 (en) | 2002-09-11 | 2004-03-25 | Johnson & Johnson Medical Limited | Wound dressing materials comprising complexes of anionic polysaccharides with silver |
GB2392913A (en) * | 2002-09-11 | 2004-03-17 | Johnson & Johnson Medical Ltd | Complex of an anionic polysaccharide with silver |
WO2004084961A1 (en) * | 2003-03-28 | 2004-10-07 | Coloplast A/S | A wound dressing |
US8124826B2 (en) | 2003-11-18 | 2012-02-28 | Systagenix Wound Management (Us), Inc. | Antioxidant and antimicrobial wound dressing materials |
US10143771B2 (en) | 2003-11-18 | 2018-12-04 | Kci Usa, Inc. | Antioxidant and antimicrobial wound dressing materials |
EP2359784B1 (en) | 2005-11-02 | 2017-09-27 | BSN medical GmbH | Absorption body for attachment to human or animal skin surfaces |
EP1942851B1 (en) | 2005-11-02 | 2016-11-23 | BSN medical GmbH | Absorptive element to be mounted on human or animal skin surfaces |
US10166147B2 (en) | 2005-11-02 | 2019-01-01 | Bsn Medical Gmbh | Absorbent article for application to human or animal skin surfaces |
US10327955B2 (en) | 2005-11-02 | 2019-06-25 | Bsn Medical Gmbh | Absorbent article for application to human or animal skin surfaces |
US8507652B2 (en) | 2008-02-08 | 2013-08-13 | Luis Eduardo da Cruz | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix |
JP2011511013A (en) * | 2008-02-08 | 2011-04-07 | エデュアルド ダ クルス,ルイス | Pharmaceutical compositions, dressings and methods for treating skin lesions, intermediate compositions and processes for preparing the dressings, and use of cerium salts in combination with a collagen matrix |
WO2009097672A3 (en) * | 2008-02-08 | 2010-05-20 | Luiz Eduardo Da Cruz | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix |
WO2009097672A2 (en) * | 2008-02-08 | 2009-08-13 | Luiz Eduardo Da Cruz | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix |
US11061033B2 (en) | 2016-04-05 | 2021-07-13 | University of Pittsburgh—of the Commonwealth System of Higher Education | Assay for detection of bladder or prostate cancer |
WO2018214007A1 (en) | 2017-05-23 | 2018-11-29 | 惠州华阳医疗器械有限公司 | Antibacterial wound dressing and preparation method and application thereof |
US11129847B2 (en) | 2017-05-23 | 2021-09-28 | Huizhou Foryou Medical Devices Co., Ltd. | Antibacterial wound dressing, method for preparing the same, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
GB9001878D0 (en) | 1990-03-28 |
AU7227991A (en) | 1991-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991011206A1 (en) | Alginate materials | |
DE4026153C2 (en) | ||
AU2017201139B2 (en) | Hemostatic Devices | |
JP4339592B2 (en) | Medical bandages containing antimicrobial silver compounds | |
CA2490847C (en) | Antimicrobial, silver-containing wound dressing for continuous release | |
EP0901382B1 (en) | Reinforced hydrogels | |
PL207044B1 (en) | Wound dressing materials comprising complexes of anionic polysaccharides with silver | |
CN1568191A (en) | Light stabilized antimicrobial materials | |
KR101865781B1 (en) | Hydrogel comprising oxidized polysaccharide and amine-modified hyaluronic acid for wound dressings and manufacturing method thereof | |
KR102264090B1 (en) | Antimicrobial hydrogel with metal organic frameworks | |
JP4808402B2 (en) | Wound dressing material containing a complex of anionic polysaccharide and silver | |
US20200306289A1 (en) | Wound healing topical formulation and preparation thereof | |
EP0165074B1 (en) | Absorbent polymer material and its preparation | |
JP3999823B2 (en) | Cross-linked polysaccharide, process for producing the same and composite material thereby | |
US6692775B2 (en) | Bactericidal gel and method for treating burns and dermal lesions | |
JPH10140472A (en) | Antimicrobial fiber and antimicrobial filtration material and their production | |
CN111012942A (en) | Hemostatic microsphere for bleeding of artery and vein and viscera and preparation method thereof | |
CN114848890B (en) | Antibacterial dressing capable of being dissolved as required and preparation method thereof | |
KR20010001271A (en) | Antibacterial agent based on Ag-alginate to be used for fiber | |
JP2919516B2 (en) | Artificial skin and method for producing the same | |
CN109381733A (en) | A kind of controllable kaolin of surface roughness/Calcium alginate film hemostatic and antibacterial dressing preparation method | |
JPH07155369A (en) | Wound coating material | |
JPS6244258A (en) | Medical living body surface covering material | |
EP4134107A1 (en) | Wound dressing comprising a hydrogel layer and a wound contact layer comprising hyaluronic acid | |
CN116019970A (en) | Method for producing high-oxygen-content aqueous gel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO PL RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: CA |